Global Cancer Monoclonal Antibodies Pipeline Analysis

In the past few years monoclonal antibodies have emerged as a therapeutic modality for cancer. These monoclonal antibodies are designed to selectively target cancer cells and extract various responses, thus indirectly protecting the non cancerous cells. This characteristic of monoclonal antibodies coupled with increasing potential of the oncology market has made many pharmaceutical giants to invest a significant portion of their R&D on cancer monoclonal antibodies.

In recent years the popularity of monoclonal antibodies has increase many folds as they have revolutionized the treatments for cancer. The applications of Monoclonal antibodies, which are administered intravenously, include cancer cell marking, growth signal blocking, the delivery of chemotherapy toxins, and the reduction of new blood vessel growth. The understanding of these treatments is rapidly becoming an indispensable part of biotech investing, and investors need to clearly understand how monoclonal antibodies are affecting the industry.

Download Report:

http://www.pnspharma.com/buy-report.php?reporttitle=Global-Cancer-Monoclonal-Antibodies-Pipeline-Analysis

“Global Cancer Monoclonal Antibodies Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various Monoclonal Antibodies being developed for the treatment of Cancer. Research report covers all the ongoing Monoclonal Antibodies being developed in various clinical development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Cancer Monoclonal Antibodies market based upon development process.

Following parameters for each Monoclonal Antibodies drug profile in development phase are covered in “Global Cancer Monoclonal Antibodies Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Orphan Designation

• Patent Information

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes

Global Cancer Monoclonal Antibodies Drug Pipeline by Clinical Phase:

• Research: 68

• Preclinical: 240

• Phase-I: 112

• Phase-I/II: 29

• Phase-II: 73

• Phase-II/III: 5

• Phase-III: 31

• Preregistration: 3

• Marketed: 27

For Report Sample Contact: rajesh@pnspharma.com or :Visit :
https://www.pnspharma.com

Recent Publication

* Global Peptide Therapeutics Market & Clinical Trials Insight
* Global Orphan Drug Clinical Pipeline Insight 2022

PNS Pharma is a pioneer in offering exclusive research reports for the pharmaceuticals industry. PNS Pharma offers Syndicated Research Reports on Drug Pipeline and Company Pipeline Analysis. These reports include comprehensive information related to the development of various drugs across clinical pipeline. Further, the reports include details on the originator, Owner, License, Chemical Formula, Patent Information, Phase of development, and Phase of development by country for each specific drug. The reports on company pipeline include all the drugs developed by particular companies across different therapeutic segments and phases and in different countries.

Rajesh Arora
rajesh@pnspharma.com
PNS Pharma
8-9, Ansal Building
Dr. Mukherjee Nagar
Delhi, India

This release was published on openPR.